Insider Selling Surge at Organogenesis Holdings Inc.
On February 15 2026, Chief Financial Officer Francisco David executed four sizable sell transactions, liquidating 53,398 shares of the company’s Class A common stock at an average price of $3.73. This activity came amid a broader wave of insider selling that saw senior executives—including the COO, VP of Strategy, and CEO—each divesting significant positions on the same day. The cumulative volume of shares sold by the top six insiders totaled more than 400,000, a sharp uptick compared with prior months when insider transactions averaged under 50,000 shares.
What Does the Sell‑Off Signal?
Insider selling is often interpreted as a lack of confidence in near‑term prospects. While the price movement was modest (the stock closed at $3.74, a 2.13 % weekly gain), the negative price‑to‑earnings ratio of –48.46 and continued net losses suggest that management may anticipate further earnings deterioration. The fact that CFO David sold at the same price that the market was trading at, coupled with a 0.03 % price change and a neutral sentiment (+10) on social media, indicates that the sales were likely driven by portfolio rebalancing rather than a strategic pivot. Nevertheless, the high volume of shares offloaded by senior executives signals to investors that the company’s leadership may be concerned about the sustainability of its current valuation trajectory.
Impact on Investors and Shareholder Value
For shareholders, the immediate effect is a dilution of ownership concentration: the insiders’ stake shrinks from roughly 18 % to 15 % in the case of CFO David, and the aggregate insider holdings fell from 2.1 million shares to about 1.8 million. While this dilution is modest, it may influence the stock’s liquidity profile and the perceived confidence of the management team. Investors who were already wary of the company’s negative earnings multiples might view this sell‑off as confirmation of a bearish outlook, potentially leading to a short‑term price correction. Conversely, some market participants may see the insider liquidity as a short‑squeeze opportunity, particularly if the company’s regenerative medicine pipeline is expected to generate a positive catalyst in the coming quarters.
Looking Ahead
Organogenesis’s valuation remains below its 52‑week low, and the company’s market cap of $473 million reflects a cautious market stance. Unless the company announces a breakthrough clinical result or a strategic partnership that could justify a higher price‑to‑earnings multiple, the insider selling trend is likely to persist. Investors should monitor subsequent filings—especially any shift in the CEO’s or CFO’s holdings—and keep an eye on quarterly earnings for signs of cost containment or revenue growth that could offset the current negative profitability profile.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-02-15 | Francisco David (Chief Financial Officer) | Sell | 3,898.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Francisco David (Chief Financial Officer) | Sell | 21,412.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Francisco David (Chief Financial Officer) | Sell | 13,369.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Francisco David (Chief Financial Officer) | Sell | 13,769.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Bilbo Patrick (Chief Operating Officer) | Sell | 5,114.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Bilbo Patrick (Chief Operating Officer) | Sell | 28,331.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Bilbo Patrick (Chief Operating Officer) | Sell | 15,617.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Bilbo Patrick (Chief Operating Officer) | Sell | 15,352.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Cavorsi Robert (Vice President, Strategy) | Sell | 6,667.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Cavorsi Robert (Vice President, Strategy) | Sell | 5,549.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Cavorsi Robert (Vice President, Strategy) | Sell | 5,442.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Freedman Lori (Chief Admin. and Legal Officer) | Sell | 4,043.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Freedman Lori (Chief Admin. and Legal Officer) | Sell | 24,428.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Freedman Lori (Chief Admin. and Legal Officer) | Sell | 12,761.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Freedman Lori (Chief Admin. and Legal Officer) | Sell | 13,510.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Gillheeney Gary S. (President and CEO) | Sell | 24,340.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Gillheeney Gary S. (President and CEO) | Sell | 78,646.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Gillheeney Gary S. (President and CEO) | Sell | 82,815.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Gillheeney Gary S. (President and CEO) | Sell | 85,605.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Grow Brian (Chief Commercial Officer) | Sell | 3,346.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Grow Brian (Chief Commercial Officer) | Sell | 18,910.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Grow Brian (Chief Commercial Officer) | Sell | 10,559.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Grow Brian (Chief Commercial Officer) | Sell | 11,144.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Montecalvo Antonio S. (Vice President, Health Policy) | Sell | 1,389.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Montecalvo Antonio S. (Vice President, Health Policy) | Sell | 9,607.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Montecalvo Antonio S. (Vice President, Health Policy) | Sell | 4,100.00 | 3.73 | Class A Common Stock |
| 2026-02-15 | Montecalvo Antonio S. (Vice President, Health Policy) | Sell | 3,523.00 | 3.73 | Class A Common Stock |
